Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutetium 177 rosopatamab tetraxetan - Telix Pharmaceuticals

Drug Profile

Lutetium 177 rosopatamab tetraxetan - Telix Pharmaceuticals

Alternative Names: 177-Lu-DOTA-Rosopatamab - Telix Pharmaceuticals; 177Lu-DOTA-rosopatamab; 177Lu-DOTA-rosopatamb; 177Lu-DOTA-TLX591; 177Lu-DOTA-TLX591-CHO; 177Lu-TLX-591; Lutetium 177 DOTA rosopatamab - Telix Pharmaceuticals; Lutetium 177 rosopatamab - Telix Pharmaceuticals; TLX 591; TLX591t; TX591

Latest Information Update: 24 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Telix Pharmaceuticals
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 19 Oct 2023 Efficacy, and adverse events and pharmacokinetics data from a phase-I ProstACT-SELECT trial in Prostate cancer released by Telix Pharmaceuticals
  • 18 Oct 2023 Telix Pharmaceuticals plans to file IND application for Phase-III PROSTACT trial in Prostate cancer (Metastatic disease, Hormone refractory, Second-line therapy or greater, Combination therapy) in the US in Q4 2023
  • 18 Oct 2023 Telix Pharmaceuticals plans the phase III PROSTACT trial in Prostate cancer (Metastatic disease, Hormone refractory, Second-line therapy or greater, Combination therapy) in the US
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top